Healing Diabetic Foot Ulcers with Semaglutide

Condition studied

Diabetic foot ulcer

Investigational medicinal product(s)

Eligibility

Primary endpoint

Time (in weeks) to wound closure in patients with a DFU using semaglutide versus standard of care treatment.

Endpoint detail

Rate of >50% reduction in ulcer surface area after 6 week of treatment between study groups (excluding newly formed ulcers), Ulcer surface area and depth at every outpatient clinic (relative to baseline), The change in ankle-brachial index/toe pressure measurements over time (at inclusion, and after wound closure of 6 months of follow-up), Rate of lower limb amputation, Rate of endovascular intervention in lower extremities, Rate of infection